Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer

Inclusion Criteria: * History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease. Confirmation of diagnosis must be performed at MSKCC. * Patient's liver metastases must be deemed unresectable and comprise \<70% of the liver parenchyma. * A patient may have had prior chemotherapy or be previously untreated. * Patient may not have received prior treatment with FUDR or \>2 doses of Oxaliplatin. * KPS \> or = to 60%. * WBC \> or = to 3,000 cells/mm3 and platelet count \> or = to 100,000 cells/mm3 within 14 days of registration. * Creatinine \< or = to 1.5 mg/dl within 14 days of registration. * Total serum bilirubin \< or = 2.0 mg/dl within 14 days of registration. Exclusion Criteria: * No active concurrent malignancies: except a patient's potentially resectable colorectal primary. * Patient must not have obstruction of GI or GU tract. * Patient must not have current, symptomatic peripheral sensory neuropathy. * No prior radiation to liver. * No active infection, ascites, or hepatic encephalopathy. * Age ≥ 18 years. * Female patients cannot be pregnant or lactating. * Signed informed consent.